ADC-Kombination bewährt sich in der Erstlinie bei HER2-positivem Brustkrebs

Im Focus Onkologie 2026

View at publisher
Authors: Thomas Müller
DOI: 10.1007/s15015-025-4478-5
Cited by: 0

Fields of Study & Subjects

HER2/EGFR in Cancer Research Breast Cancer Treatment Studies Gastric Cancer Management and Outcomes

Publication details

Journal / source
Im Focus Onkologie
Volume
29
Issue
1-2
Pages
17–17
Publication date
1 February 2026
Language
DE